Prospective clinical study of Jiedu Tongluo Tiaogan Decoction in intervention of type 2 diabetes complicated with lower extremity arteriosclerosis obliterans and its mechanism exploration

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051337

Enrollment

Unknown

Registered

2021-09-20

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes complicated with lower extremity arteriosclerosis obliterans

Interventions

Healthy people group:None

Control group:Conventional basic treatment of western medicine

Traditional Chinese medicine treatment group:Conventional basic western medicine treatment and Jiedu Tongluo Tiaogan Decoction

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Traditional Chinese medicine treatment group and control group: 1.Aged above 18 years old; 2.Conform to the diagnostic criteria for type 2 diabetes and type 2 diabetes lower extremity arterial occlusion; 3.Patients with normal liver and kidney function; 4.Sign informed consent. Healthy control group: Have been diagnosed to exclude diabetes after examination.

Exclusion criteria

Exclusion criteria: Traditional Chinese medicine treatment group and control group: 1.Combined with serious primary diseases such as heart, brain, liver, kidney, hematopoietic system, etc., Severe coagulation disorder, mental illness, or other conditions or contraindications that may affect clinical research as judged by the investigator; 2.Thromboangiitis obliterans, aortic arteritis, Raynauds disease, cold injury vascular disease and other ischemic diseases Disease; 3.Pregnancy or breastfeeding, or planning to become pregnant within 6 months; 4.Severe allergies, known or likely to be allergic to the test drug or its components; 5.Participants in other clinical trials in the last three months; 6.Serious cardiovascular and cerebrovascular diseases, such as stroke, transient ischemic attack, coronary heart disease, myocardial infarction, etc. Healthy group: 1.Patients with diabetes or substantial disease of the heart, brain, liver, kidney and other important organs, and history of other major diseases; 2.Have taken hypoglycemic drugs.

Design outcomes

Primary

Measure	Time frame
glycosylated hemoglobin;high density lipoprotein cholesterol;triglyceride;hypersensitive C-reactive protein;homocysteine;	—

Secondary

Measure	Time frame
fasting blood-glucose;cholestenone;low density lipoprotein cholesterin;body mass index;	—

Countries

China

Contacts

Public ContactPiao Chunli

Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine

pcl2013@sina.cn+86 18819075590

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026